Pelthos Therapeutics (PTHS) Accumulated Expenses (2022 - 2026)

Pelthos Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $15.4 million for Q4 2025.

• In Q4 2025, Accumulated Expenses changed N/A year-over-year to $15.4 million; the TTM figure through Dec 2025 stood at $15.4 million (changed N/A YoY), while the FY2025 annual figure was $15.4 million, changed N/A from the prior year.
• Accumulated Expenses for Q4 2025 stood at $15.4 million, up from $11.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $15.4 million in Q4 2025, with the low at $308.0 in Q3 2024.
• The 4-year median for Accumulated Expenses is $428676.5 (2024), against an average of $3.6 million.
• Peak annual rise in Accumulated Expenses reached 3860289.61% in 2025, while the deepest fall reached 93.5% in 2025.
• Pelthos Therapeutics' Accumulated Expenses stood at $221875.0 in 2022, then jumped by 191.13% to $645947.0 in 2023, then slumped by 99.95% to $308.0 in 2024, then surged by 4988211.69% to $15.4 million in 2025.
• Business Quant data shows PTHS's Accumulated Expenses at $15.4 million in Q4 2025, $11.9 million in Q3 2025, and $23636.0 in Q2 2025.